International Rescue Committee (IRC) and Partners Launch PlayMatters 3.0 to Expand Learning through Play across East Africa ...

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily ...

An evidence-based website could help patients better understand these treatments ...

New obesity drugs are posting surgical-scale weight-loss numbers. Is the gap closing, or are we mistaking early results for the final answer?

Atom Therapeutics, an innovative biotechnology company focused on the discovery and development of novel therapies for metabolic, inflammatory, and cardiovascular diseases, today announced the ...

Millions of people now take semaglutide for weight loss or cardiovascular risk reduction, and a growing body of ...

Qure may seek approval in the UK first while in talks with the FDA about its request for a larger, sham-controlled trial of ...

Vivani CEO Adam Mendelsohn, Ph.D., stated, “HREC approval to initiate SLIM-1 in Australia marks an important moment for our Company, clearing the way for near-term, mid-2026, initiation. We are eager ...

BROADEN2 enrollment completed nearly six months ahead of anticipated timelines. KT-621 Phase 3 trials in AD planned to initiate by mid-2027. KT-621 BREADTH Phase 2b asthma trial o ...

Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion ...

ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America ...

Viking Therapeutics starts Phase 1 study on novel weight loss drug in healthy adults: San Diego Thursday, June 25, 2026, 18:00 Hrs [IST] Viking Therapeutics, Inc., a clinical-stag ...